| Sep 25 |
Amgen claims success for two immune drugs, but results underwhelm Wall Street
|
| Sep 24 |
Amgen stock slips 3% following Phase 3 data for rocatinlimab, Uplizna
|
| Sep 24 |
Amgen gets Japanese approval of Tepezza for thyroid eye disease
|
| Sep 24 |
TEPEZZA® (TEPROTUMUMAB) RECEIVES APPROVAL IN JAPAN FOR THE TREATMENT OF ACTIVE THYROID EYE DISEASE
|
| Sep 24 |
Regeneron Stock Down on Court Ruling for Amgen's Biosimilar of Eylea
|
| Sep 24 |
Amgen (NASDAQ:AMGN) shareholders have earned a 15% CAGR over the last five years
|
| Sep 24 |
Regeneron downgraded at Leerink after Amgen’s court win; Truist defends
|
| Sep 24 |
2 Weight Loss Stocks That Could Rocket Higher This Year
|
| Sep 23 |
Amgen (AMGN) Stock Declines While Market Improves: Some Information for Investors
|
| Sep 23 |
Regeneron Dives As Amgen Tees Up Its Rival To Moneymaking Machine Eylea
|
